A Double-Blind Randomized Controlled Trial of Oxytocin Nasal Spray and Social Cognition Training for Young People with Early Psychosis

Cristina Cacciotti-Saija, Robyn Langdon, Philip B. Ward, Ian B. Hickie, Elizabeth M. Scott, Sharon L. Naismith, Loretta Moore, Gail A. Alvares, Marie Antoinette Redoblado Hodge, Adam J. Guastella

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Social-cognitive deficits contribute to poor functional outcomes in early psychosis; however, no effective pharmacological treatments exist for these problems. This study was the first to investigate the efficacy of an extended treatment of oxytocin nasal spray combined with social cognition training (SCT) to improve social cognition, clinical symptoms, and social functioning in early psychosis. In a double-blind, randomized, placebo-controlled, between-subjects trial, 52 individuals (aged 16-35 years) diagnosed with an early psychosis schizophrenia-spectrum illness were recruited. Participants received oxytocin (24 International Units) or placebo nasal spray twice-daily for 6 weeks, combined with group SCT (2 × 1 hour weekly sessions for 6 weeks). An additional dose of oxytocin was administered before each weekly session. Assessments were conducted at baseline, post-treatment, and at 3-month follow-up. Primary outcomes included the Reading the Mind in the Eyes Test, the Scale for the Assessment of Positive and Negative Symptoms, and the Social Functioning Scale. Secondary outcomes included self-report and behavioral assessments of social cognition, symptom severity, and social functioning. Results showed that on all primary and secondary outcomes, there was no benefit of oxytocin nasal spray treatment in comparison to placebo. Exploratory post hoc analysis suggested that increased use of nasal spray was, however, associated with reductions in negative symptoms in the oxytocin condition only. This study represents the first evaluation of oxytocin treatment for early psychosis. Although results suggest no benefit of oxytocin treatment, results also highlight an urgent need to consider nasal spray delivery and dose-related variables for future clinical trials.

Original languageEnglish
Pages (from-to)483-493
Number of pages11
JournalSchizophrenia Bulletin
Volume41
Issue number2
DOIs
Publication statusPublished - 1 Mar 2015
Externally publishedYes

Fingerprint

Nasal Sprays
Oxytocin
Psychotic Disorders
Cognition
Randomized Controlled Trials
Placebos
Therapeutics
Self Report
Reading
Schizophrenia
Clinical Trials
Pharmacology

Cite this

Cacciotti-Saija, C., Langdon, R., Ward, P. B., Hickie, I. B., Scott, E. M., Naismith, S. L., ... Guastella, A. J. (2015). A Double-Blind Randomized Controlled Trial of Oxytocin Nasal Spray and Social Cognition Training for Young People with Early Psychosis. Schizophrenia Bulletin, 41(2), 483-493. https://doi.org/10.1093/schbul/sbu094
Cacciotti-Saija, Cristina ; Langdon, Robyn ; Ward, Philip B. ; Hickie, Ian B. ; Scott, Elizabeth M. ; Naismith, Sharon L. ; Moore, Loretta ; Alvares, Gail A. ; Redoblado Hodge, Marie Antoinette ; Guastella, Adam J. / A Double-Blind Randomized Controlled Trial of Oxytocin Nasal Spray and Social Cognition Training for Young People with Early Psychosis. In: Schizophrenia Bulletin. 2015 ; Vol. 41, No. 2. pp. 483-493.
@article{056f68cb528c4d3eb9fa7672e99117d7,
title = "A Double-Blind Randomized Controlled Trial of Oxytocin Nasal Spray and Social Cognition Training for Young People with Early Psychosis",
abstract = "Social-cognitive deficits contribute to poor functional outcomes in early psychosis; however, no effective pharmacological treatments exist for these problems. This study was the first to investigate the efficacy of an extended treatment of oxytocin nasal spray combined with social cognition training (SCT) to improve social cognition, clinical symptoms, and social functioning in early psychosis. In a double-blind, randomized, placebo-controlled, between-subjects trial, 52 individuals (aged 16-35 years) diagnosed with an early psychosis schizophrenia-spectrum illness were recruited. Participants received oxytocin (24 International Units) or placebo nasal spray twice-daily for 6 weeks, combined with group SCT (2 × 1 hour weekly sessions for 6 weeks). An additional dose of oxytocin was administered before each weekly session. Assessments were conducted at baseline, post-treatment, and at 3-month follow-up. Primary outcomes included the Reading the Mind in the Eyes Test, the Scale for the Assessment of Positive and Negative Symptoms, and the Social Functioning Scale. Secondary outcomes included self-report and behavioral assessments of social cognition, symptom severity, and social functioning. Results showed that on all primary and secondary outcomes, there was no benefit of oxytocin nasal spray treatment in comparison to placebo. Exploratory post hoc analysis suggested that increased use of nasal spray was, however, associated with reductions in negative symptoms in the oxytocin condition only. This study represents the first evaluation of oxytocin treatment for early psychosis. Although results suggest no benefit of oxytocin treatment, results also highlight an urgent need to consider nasal spray delivery and dose-related variables for future clinical trials.",
keywords = "emotion recognition, neuropeptides, schizophrenia, social behavior",
author = "Cristina Cacciotti-Saija and Robyn Langdon and Ward, {Philip B.} and Hickie, {Ian B.} and Scott, {Elizabeth M.} and Naismith, {Sharon L.} and Loretta Moore and Alvares, {Gail A.} and {Redoblado Hodge}, {Marie Antoinette} and Guastella, {Adam J.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1093/schbul/sbu094",
language = "English",
volume = "41",
pages = "483--493",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "OXFORD UNIV PRESS UNITED KINGDOM",
number = "2",

}

Cacciotti-Saija, C, Langdon, R, Ward, PB, Hickie, IB, Scott, EM, Naismith, SL, Moore, L, Alvares, GA, Redoblado Hodge, MA & Guastella, AJ 2015, 'A Double-Blind Randomized Controlled Trial of Oxytocin Nasal Spray and Social Cognition Training for Young People with Early Psychosis' Schizophrenia Bulletin, vol. 41, no. 2, pp. 483-493. https://doi.org/10.1093/schbul/sbu094

A Double-Blind Randomized Controlled Trial of Oxytocin Nasal Spray and Social Cognition Training for Young People with Early Psychosis. / Cacciotti-Saija, Cristina; Langdon, Robyn; Ward, Philip B.; Hickie, Ian B.; Scott, Elizabeth M.; Naismith, Sharon L.; Moore, Loretta; Alvares, Gail A.; Redoblado Hodge, Marie Antoinette; Guastella, Adam J.

In: Schizophrenia Bulletin, Vol. 41, No. 2, 01.03.2015, p. 483-493.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Double-Blind Randomized Controlled Trial of Oxytocin Nasal Spray and Social Cognition Training for Young People with Early Psychosis

AU - Cacciotti-Saija, Cristina

AU - Langdon, Robyn

AU - Ward, Philip B.

AU - Hickie, Ian B.

AU - Scott, Elizabeth M.

AU - Naismith, Sharon L.

AU - Moore, Loretta

AU - Alvares, Gail A.

AU - Redoblado Hodge, Marie Antoinette

AU - Guastella, Adam J.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Social-cognitive deficits contribute to poor functional outcomes in early psychosis; however, no effective pharmacological treatments exist for these problems. This study was the first to investigate the efficacy of an extended treatment of oxytocin nasal spray combined with social cognition training (SCT) to improve social cognition, clinical symptoms, and social functioning in early psychosis. In a double-blind, randomized, placebo-controlled, between-subjects trial, 52 individuals (aged 16-35 years) diagnosed with an early psychosis schizophrenia-spectrum illness were recruited. Participants received oxytocin (24 International Units) or placebo nasal spray twice-daily for 6 weeks, combined with group SCT (2 × 1 hour weekly sessions for 6 weeks). An additional dose of oxytocin was administered before each weekly session. Assessments were conducted at baseline, post-treatment, and at 3-month follow-up. Primary outcomes included the Reading the Mind in the Eyes Test, the Scale for the Assessment of Positive and Negative Symptoms, and the Social Functioning Scale. Secondary outcomes included self-report and behavioral assessments of social cognition, symptom severity, and social functioning. Results showed that on all primary and secondary outcomes, there was no benefit of oxytocin nasal spray treatment in comparison to placebo. Exploratory post hoc analysis suggested that increased use of nasal spray was, however, associated with reductions in negative symptoms in the oxytocin condition only. This study represents the first evaluation of oxytocin treatment for early psychosis. Although results suggest no benefit of oxytocin treatment, results also highlight an urgent need to consider nasal spray delivery and dose-related variables for future clinical trials.

AB - Social-cognitive deficits contribute to poor functional outcomes in early psychosis; however, no effective pharmacological treatments exist for these problems. This study was the first to investigate the efficacy of an extended treatment of oxytocin nasal spray combined with social cognition training (SCT) to improve social cognition, clinical symptoms, and social functioning in early psychosis. In a double-blind, randomized, placebo-controlled, between-subjects trial, 52 individuals (aged 16-35 years) diagnosed with an early psychosis schizophrenia-spectrum illness were recruited. Participants received oxytocin (24 International Units) or placebo nasal spray twice-daily for 6 weeks, combined with group SCT (2 × 1 hour weekly sessions for 6 weeks). An additional dose of oxytocin was administered before each weekly session. Assessments were conducted at baseline, post-treatment, and at 3-month follow-up. Primary outcomes included the Reading the Mind in the Eyes Test, the Scale for the Assessment of Positive and Negative Symptoms, and the Social Functioning Scale. Secondary outcomes included self-report and behavioral assessments of social cognition, symptom severity, and social functioning. Results showed that on all primary and secondary outcomes, there was no benefit of oxytocin nasal spray treatment in comparison to placebo. Exploratory post hoc analysis suggested that increased use of nasal spray was, however, associated with reductions in negative symptoms in the oxytocin condition only. This study represents the first evaluation of oxytocin treatment for early psychosis. Although results suggest no benefit of oxytocin treatment, results also highlight an urgent need to consider nasal spray delivery and dose-related variables for future clinical trials.

KW - emotion recognition

KW - neuropeptides

KW - schizophrenia

KW - social behavior

UR - http://www.scopus.com/inward/record.url?scp=84940825450&partnerID=8YFLogxK

U2 - 10.1093/schbul/sbu094

DO - 10.1093/schbul/sbu094

M3 - Article

VL - 41

SP - 483

EP - 493

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 2

ER -